Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 42 Parkinson Disease 4, Autosomal Dominant Lewy Body 29 Carcinoma, Renal Cell 26 Endometrial Neoplasms 13 Melanoma 10 Neoplasms 8 Uterine Cervical Neoplasms 7 Cholangiocarcinoma 7 Biliary Tract Neoplasms 7 Liver Neoplasms 6 Stomach Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Neuroendocrine Tumors 5 Triple Negative Breast Neoplasms 4 Thyroid Neoplasms 4 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Esophageal Squamous Cell Carcinoma 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Thyroid Carcinoma, Anaplastic 3 Recurrence 3 Kidney Neoplasms 3 Esophageal Neoplasms 3 Diabetes Mellitus, Insulin-Dependent, 12 3 Carcinoma, Adenoid Cystic 3 Breast Neoplasms 3 Brain Neoplasms 3 Adenocarcinoma 3 Vulvar Neoplasms 2

Interventions

pembrolizumab 88 Carboplatin 77 Specimen Handling 76 Magnetic Resonance Spectroscopy 63 Pemetrexed 59 Cisplatin 47 durvalumab 44 Paclitaxel 38 Nivolumab 34 atezolizumab 32 osimertinib 29 Radiotherapy 29 Radiosurgery 29 Biopsy 26 Blood Specimen Collection 25 Gemcitabine 24 Docetaxel 24 Immunoglobulin G 23 Disulfides 22 Standard of Care 21 Drug Therapy 21 Etoposide 19 Taxes 18 Practice Guidelines as Topic 18 Radiation 17 Educational Status 16 130-nm albumin-bound paclitaxel 15 X-Rays 14 Surveys and Questionnaires 14 Bevacizumab 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × lenvatinib × 1 year × Clear all

NCT05384015 2026-04-30

PEERS

Fundación GECP

Phase 2 Active not recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡